Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791349 | 1.00 | ALDH1A1 (0.56) | ALDH1A1TDP1LMNASIRT6L3MBTL1 | |
| SCHEMBL30578620 | 0.88 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNASIRT6L3MBTL1 | |
| SCHEMBL30184611 | 0.88 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNASIRT6L3MBTL1 | |
| SCHEMBL311157 | 0.85 | ALDH1A1 (0.56) | ALDH1A1TDP1LMNAABCB1ABCC1 | |
| SCHEMBL30193867 | 0.85 | ALDH1A1 (0.56) | ALDH1A1TDP1LMNAABCB1ABCC1 | |
| SCHEMBL1298919 | 0.84 | MERTK (0.49) | ALDH1A1TDP1LMNAL3MBTL1MAPT | |
| SCHEMBL205073 | 0.83 | S100A4 (0.51) | ALDH1A1TDP1LMNAL3MBTL1ABCB1 | |
| SCHEMBL22897608 | 0.82 | MAPT (0.42) | ALDH1A1TDP1LMNASIRT6L3MBTL1 | |
| SCHEMBL47017 | 0.82 | L3MBTL1 (0.55) | ALDH1A1TDP1LMNAL3MBTL1ABCB1 | |
| SCHEMBL11224598 | 0.81 | CHEK1 (0.61) | ALDH1A1TDP1LMNASIRT6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635942-A1 | QUINOLINE DERIVATIVE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Carephar Pharmaceutical Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| US-20250257070-A1 | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT | HANMI PHARM. CO., LTD. (KR) | 2025-08-14 | — | — | US | disclosed |
| US-12319695-B2 | Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect | HANMI PHARM. CO., LTD. (KR) | 2025-06-03 | — | — | US | disclosed |
| CN-119968361-A | Compounds targeting p 53Y 220 mutants | 北京加科思新药研发有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025082353-A1 | POLYMORPHIC FORMS OF THE COMPOUNDS TARGETING MUTANT OF P53 AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-24 | — | — | WO | disclosed |
| US-20250026722-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Université Côte d’Azur (FR) | 2025-01-23 | — | — | US | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| WO-2024152743-A1 | QUINOLINE DERIVATIVE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏柯菲平医药股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-118373771-A | Quinoline derivative compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 江苏柯菲平医药股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| EP-4399202-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Yukin Therapeutics (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-20030100560-A1 | Heterocyclic cytotoxic agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2003-05-29 | — | — | US | disclosed |
| EP-1089735-A4 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARMY, UNITED STATES | 2002-10-24 | — | — | US | disclosed |
| EP-1228045-A2 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002036588-A2 | REVERSED AMIDINES AND METHODS OF USING FOR TREATING, PREVENTING, OR INHIBITING LEISHMANIASIS | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) | 2002-05-10 | — | — | WO | disclosed |
| US-6284774-B1 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-09-04 | — | — | US | disclosed |
| CN-1304307-A | 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists | WARNER LAMBER CO (US) | 2001-07-18 | — | — | CN | disclosed |
| WO-2001032631-A2 | HETEROCYCLIC CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JEREY (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-1089735-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | Warner-Lambert Company LLC (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000197-A1 | 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026722-A1 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | NFKBIA, IKBKG, IKBKB | ALDH1A1 4682/4885TDP1 2063/4885LMNA 1610/4885 |
| US-12319695-B2 | Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect | EGFR, FGFR1, FGFR3 | ALDH1A1 3515/4885TDP1 2481/4885LMNA 4573/4885 |
| US-20250257070-A1 | NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT | EGFR, FGFR1, FGFR3 | ALDH1A1 3055/4885TDP1 2738/4885LMNA 4590/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | ALDH1A1 2527/4885TDP1 412/4885LMNA 922/4885 |
| US-20030100560-A1 | Heterocyclic cytotoxic agents | CCNA1, CCNE1, MCL1 | ALDH1A1 114/4885TDP1 563/4885LMNA 1211/4885 |
| US-20020156098-A1 | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | ARG1, NAT1, CTSA | ALDH1A1 3016/4885TDP1 1890/4885LMNA 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.